Technology | Mammography | December 07, 2018

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

Artificial intelligence-based technology improves cancer detection rates 8 percent on average, decreases unnecessary patient recalls 7 percent

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

December 7, 2018 — iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI. The solution built on artificial intelligence (AI) is now available to healthcare facilities in the U.S.

The FDA clearance is based on positive clinical results from a large reader study completed earlier this year and presented at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. The research was performed with 24 radiologists who read 260 tomosynthesis cases both with and without iCAD’s ProFound AI solution. The findings show increased cancer detection rates, reduced false positive rates and patient recalls, and a significant decrease in interpretation times.

“This technology shows tremendous promise in assisting radiologists in detecting cancers, reducing recalls and increasing efficiency when reading tomosynthesis studies,” said Emily Conant, M.D., professor and chief, Division of Breast Imaging, vice chair of faculty development, Department of Radiology at the Hospital of the University of Pennsylvania. “Clinical data shows that when tomosynthesis readers use the ProFound AI algorithm, case-level sensitivity is improved by 8 percent on average and reading times are significantly decreased. Radiologists with various levels of expertise may benefit from this AI-driven technology when reading large tomosynthesis data sets.”

ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT, delivering improvement of cancer detection rates by an average of 8 percent and decreasing unnecessary patient recall rates by an average of 7 percent. The new technology is trained to detect malignant soft-tissue densities and calcifications. It also provides radiologists with scoring information representing the likelihood that a detection or case is malignant based on the large dataset of clinical images used to train the algorithm.

In addition to improving clinical performance related to breast cancer detection and false positive rates, study results showed ProFound AI can reduce radiologists’ reading time by more than 50 percent on average. An increase in reading time has been a significant challenge for radiologists when moving from 2-D to 3-D mammography.

The solution is currently available for use with - DBT systems in the U.S., Canada and Europe.

For more information: www.icadmed.com

Related Content

Sectra Signs Enterprise Imaging Contract With Vanderbilt Health
News | Enterprise Imaging | August 21, 2019
Sectra will install its enterprise imaging picture archiving and communication system (PACS) and vendor neutral archive...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and
News | Cybersecurity | August 20, 2019
Healthcare data breaches are currently being reported at a rate of more than one a day, according to a new report from...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
The CT scanner might not come with protocols that are adequate for each hospital situation, so at Phoenix Children’s Hospital they designed their own protocols, said Dianna Bardo, M.D., director of body MR and co-director of the 3D Innovation Lab at Phoenix Children’s.

The CT scanner might not come with protocols that are adequate for each hospital situation, so at Phoenix Children’s Hospital they designed their own protocols, said Dianna Bardo, M.D., director of body MR and co-director of the 3D Innovation Lab at Phoenix Children’s.

Sponsored Content | Case Study | Radiation Dose Management | August 13, 2019
Radiation dose management is central to child patient safety. Medical imaging plays an increasing role in the accurate...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...